Phase II trial of BNC105P as 2nd line chemotherapy for advanced malignant pleural mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs BNC 105 (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms B2P2M2
- 17 Apr 2015 According to a Bionomics media release, biomarker data from this trial will be presented as a part of a pooled analysis of this and two other trials at the American Association for Cancer Research (AACR) 106th Annual Meeting.
- 20 Feb 2014 Status changed from active, no longer recruiting to completed, as per the Australian New Zealand Clinical Trials Registry record.
- 03 Aug 2011 Status changed from recruiting to active, no longer recruiting.